Peghin M.; Maiani M.; Castaldo N.; Givone F.; Righi E.; Lechiancole A.; Sartor A.; Pea F.; Livi U.; Bassetti M., Ceftolozane/tazobactam for the treatment of MDR Pseudomonas aeruginosa left ventricular assist device infection as a bridge to heart transplant, «INFECTION», 2018, 46, pp. 263 - 265 [replica/breve intervento]
Cojutti P.G.; Candoni A.; Lazzarotto D.; Rabassi N.; Fanin R.; Hope W.; Pea F., Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with haematological malignancies, «BRITISH JOURNAL OF CLINICAL PHARMACOLOGY», 2018, 84, pp. 2544 - 2550 [articolo]
Cojutti P.G.; Merelli M.; De Stefanis P.; Fregonese C.; Lucchese F.; Bassetti M.; Pea F., Disposition of ceftobiprole during continuous venous-venous hemodiafiltration (CVVHDF) in a single critically ill patient, «EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY», 2018, 74, pp. 1671 - 1672 [replica/breve intervento]
Cojutti P.G.; Barbarino C.; De Monte A.; Hope W.; Pea F., Higher than standard meropenem and linezolid dosages needed for appropriate treatment of an intracerebral hemorrhage patient with augmented renal clearance, «EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY», 2018, 74, pp. 1091 - 1092 [articolo]
Pea, Federico, Intracellular Pharmacokinetics of Antibacterials and Their Clinical Implications, «CLINICAL PHARMACOKINETICS», 2018, 57, pp. 177 - 189 [articolo]
Cojutti P.; Sartor A.; Bassetti M.; Scarparo C.; Pea F., Is meropenem MIC increase against KPC-producing Klebsiella pneumoniae correlated with increased resistance rates against other antimicrobials with Gram-negative activity?, «JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE», 2018, 14, pp. 238 - 241 [articolo]
Pea F; Lewis RE, Overview of antifungal dosing in invasive candidiasis, «JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY», 2018, 73, pp. i33 - i43 [articolo]
Pea F., Pharmacokinetics and drug metabolism of antibiotics in the elderly, «EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY», 2018, 14, pp. 1087 - 1100 [articolo]
Cojutti P.; Pai M.P.; Pea F., Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients, «CLINICAL PHARMACOKINETICS», 2018, 57, pp. 989 - 1000 [articolo]
Cojutti P.G.; Lugano M.; Righi E.; Della Rocca G.; Bassetti M.; Hope W.; Pea F., Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with Candida albicans and non-albicans spp, «EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY», 2018, 74, pp. 1449 - 1459 [articolo]
Concia E, Viscoli C, Del Bono V, Giannella M, Bassetti M, De Rosa GF, Durante Mangoni E, Esposito S, Giusti M, Grossi P, Menichetti F, Pea F, Petrosillo N, Tumbarello M, Stefani S, Venditti M, Viale P, The current role of glycopeptides in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in not neutropenic adults: the viewpoint of a group of Italian experts, «JOURNAL OF CHEMOTHERAPY», 2018, 30, pp. 157 - 171 [articolo]
Tangden T.; Cojutti P.G.; Roberts J.A.; Pea F., Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens, «CLINICAL PHARMACOKINETICS», 2018, 57, pp. 1399 - 1405 [articolo]
Pea F.; Cojutti P.G.; Baraldo M., A 10-Year Experience of Therapeutic Drug Monitoring (TDM) of Linezolid in a Hospital-wide Population of Patients Receiving Conventional Dosing: Is there Enough Evidence for Suggesting TDM in the Majority of Patients?, «BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY», 2017, 121, pp. 303 - 308 [articolo]
Bassetti M.; Pecori D.; Cojutti P.; Righi E.; Pea F., Clinical and pharmacokinetic drug evaluation of delafloxacin for the treatment of acute bacterial skin and skin structure infections, «EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY», 2017, 13, pp. 1193 - 1200 [articolo]
Cojutti P.; Giangreco M.; Isola M.; Pea F., Limited sampling strategies for determining the area under the plasma concentration–time curve for isoniazid might be a valuable approach for optimizing treatment in adult patients with tuberculosis, «INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS», 2017, 50, pp. 23 - 28 [articolo]
